Physician profile
Sherell Vicks
NPI 1932251253
$569.24
in general payments reported to CMS, 2019-2025
15 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $32.69 · 2021: $54.87 · 2022: $37.08 · 2023: $57.12 · 2024: $46.22 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $207.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $91.28 | 2019-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $84.22 | 2025 | Rexulti |
| Abbvie INC. | $59.87 | 2021-2023 | Ubrelvy |
| Glaxosmithkline, LLC. | $49.31 | 2022-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.80 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $39.30 | 2019 | |
| Lilly USA, LLC | $38.76 | 2019-2024 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $28.56 | 2019-2021 | |
| Allergan, INC. | $27.66 | 2019 | |
| Boston Scientific Corporation | $24.07 | 2019 | |
| Merck Sharp & Dohme LLC | $22.54 | 2019 | |
| Dexcom, INC. | $20.76 | 2024 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $17.50 | 2019 | |
| Zyla Life Sciences, INC. | $13.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherell Vicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.